General MedicationsORALGeneric
ORAGRAFIN SODIUM
IPODATE SODIUM
Standard Dose
500MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview ORAGRAFIN SODIUM is listed in Drugs@FDA under application 012967 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient IPODATE SODIUM Form and strength CAPSULE;ORAL - 500MG Sponsor BRACCO Submission history Latest submission status date: 1992-09-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview ORAGRAFIN SODIUM is listed in Drugs@FDA under application 012967 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient IPODATE SODIUM Form and strength CAPSULE;ORAL - 500MG Sponsor BRACCO Submission history Latest submission status date: 1992-09-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.